Share on StockTwits

United Therapeutics (NASDAQ:UTHR) CEO Martine A. Rothblatt sold 9,066 shares of United Therapeutics stock in a transaction that occurred on Thursday, June 5th. The shares were sold at an average price of $96.46, for a total value of $874,506.36. Following the transaction, the chief executive officer now directly owns 140 shares of the company’s stock, valued at approximately $13,504. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Several analysts have recently commented on the stock. Analysts at Zacks reiterated a “neutral” rating on shares of United Therapeutics in a research note on Tuesday, May 27th. They now have a $104.00 price target on the stock. Finally, analysts at Standpoint Research upgraded shares of United Therapeutics from a “hold” rating to a “buy” rating in a research note on Monday, April 7th. They now have a $118.00 price target on the stock. Six equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. United Therapeutics currently has an average rating of “Hold” and an average price target of $95.93.

United Therapeutics (NASDAQ:UTHR) traded up 0.29% on Thursday, hitting $96.98. The stock had a trading volume of 343,002 shares. United Therapeutics has a 1-year low of $61.23 and a 1-year high of $116.65. The stock’s 50-day moving average is $99.24 and its 200-day moving average is $99.36. The company has a market cap of $4.672 billion and a P/E ratio of 21.01.

United Therapeutics (NASDAQ:UTHR) last released its earnings data on Tuesday, April 29th. The company reported $1.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.65 by $0.12. The company had revenue of $289.40 million for the quarter, compared to the consensus estimate of $300.14 million. During the same quarter in the previous year, the company posted $1.19 earnings per share. The company’s revenue for the quarter was up 18.1% on a year-over-year basis. Analysts expect that United Therapeutics will post $7.77 EPS for the current fiscal year.

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.